Circassia Limited

Mark Larche

Roderick Peter Hafner

Paul Laidler

Anthony Barrington Kay

Guy Layton

Pascal Hickey

Paul Laider

Rod Hafner

Polypeptides which may be used for preventing or treating allergy to moulds of theand/orgenus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO: 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Cla16), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGT-GSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.

Cladosporium peptides

The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.

Peptide for vaccine

The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.

Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy

The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerization therapy.

Peptide with multiple epitopes

The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.

Vaccine peptide combinations

The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.

Peptides for vaccine against birch allergy

A first or second polypeptide for use in a method of treating or preventing a disorder by tolerization, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides:

T-cell antigen peptide from allergen for stimulation of IL-10 production

Grass peptides for vaccine

Vaccine peptide combinations against cat allergy

Vaccine comprising AMB A 1 peptides for use in the treatment of ragweed allergy

The present invention relates to immunologically cryptic peptides; methods for their identification in individuals and populations and their use in diagnosis and therapy of pathological conditions such as asthma and allergy, and their use in screening for therapeutic activity. Such cryptic peptides are identified by a method which includes the steps of: 1) exposing T cells with the peptide in a primary challenge; 2) measuring the reactivity of T cells with the peptide in the primary challenge of step 1); 3) exposing pre-challenged T cells with the peptide in a secondary challenge, wherein the pre-challenged T cells are obtainable by exposign the T cells to the protein; and measuring the reactivity of the pre-challenged T cells with the peptide in the secondary challenge of step ), and the peptide is a cryptic peptide if T-cell reactivity is observable in the secondary challenge but not in the primary challenge.

Growing community of inventors

CA

Mark Larche